Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Community Dentistry and Oral Epidemiology|October 18, 2019
Factors associated with oral health service utilization among adults and older adults in China, 2015-2016Mengru Xu, Menglin Cheng, Xiaoli Gao, et al.
Leukemia|February 20, 2024
Genomic features reveal potential benefit of adding anti-PD-1 immunotherapy to treat non-upper aerodigestive tract natural killer/T-cell lymphomaZegeng Chen, He Huang, Huageng Huang, et al.
Signal Transduction and Targeted Therapy|April 16, 2024
Phase II study of novel orally PI3Kα/δ inhibitor TQ-B3525 in relapsed and/or refractory follicular lymphomaHuaqing Wang, Jifeng Feng, Yanyan Liu, et al.
Signal Transduction and Targeted Therapy|May 16, 2024
Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II studyYan Gao, Haixia He, Xueping Li, et al.
Blood Cancer Journal|March 18, 2026
Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26)Juying Wei, Qingqing Cai, Liling Zhang, et al.
The Gerontologist|March 31, 2023
The Changing Demography of Late-Life Family Caregiving: A Research Agenda to Understand Future Care Networks for an Aging U.S. PopulationVicki A Freedman, Emily M Agree, Judith A Seltzer, et al.
Eclinicalmedicine|September 2, 2025
Efficacy and safety of tazemetostat, an EZH2 inhibitor, in Chinese patients with relapsed/refractory follicular lymphoma: a multicentre, single-arm, phase 2 studyJunning Cao, Guangliang Chen, Lihua Qiu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2023
The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical TrialTingyu Wang, Xiuhua Sun, Lihua Qiu, et al.
JAMA Oncology|February 8, 2024
Efficacy, Safety, and Population Pharmacokinetics of MW032 Compared With Denosumab for Solid Tumor-Related Bone Metastases: A Randomized, Double-Blind, Phase 3 Equivalence TrialShaohua Zhang, Yongmei Yin, Hailin Xiong, et al.
Journal of Cancer Research and Therapeutics|December 29, 2023
Chinese expert consensus on the management of patients with hematologic malignancies infected with SARS-CoV-2Jun Wang, Liang Shao, Jing Liang, et al.
Pageof 4